Psoriasis-Induced Postoperative Cardiac Failure

Jha, Pankaj K.; Das, Satish; Musleh, Ghassan; Lakshmanan, Suresh; Kingston, Timothy P.; Deiraniya, Abdul K.

doi:10.1016/j.athoracsur.2003.06.035

Cited by 8 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Jha et al 75 presented a 75-year-old woman who developed persistent severe vasodilatation after coronary artery bypass surgery, which was evoked by a flare-up of erythrodermic psoriasis. Eliakim-Raz et al 76 described four psoriasis patients who had been diagnosed with idiopathic dilated cardiomyopathy (DCM).…”

Section: Cardiovascular Risk Assessed In Selected Examinations and Ramentioning

confidence: 99%

Cardiovascular aspects of psoriasis: an updated review

et al. 2013

View full text Add to dashboard Cite

Psoriasis, a systemic inflammatory disease, is associated with enhanced atherosclerosis and risk of cardiovascular (CV) disease, which may account for higher morbidity and mortality rates in psoriatic patients. It especially applies to younger psoriatic patients with more severe disease, reducing their life expectancy. The aim of the study was to review the literature on CV disease in psoriasis as well as the pathogenic mechanisms shared between psoriasis and atherosclerosis. Moreover, case-control and cohort studies published between 2006 and 2011 were selected for meta-analysis. The meta-analysis indicates elevated risk of cardiovascular events in psoriatic patients in relation to non-psoriatic controls (OR 1.28; 95% CI 1.18-1.38). It is suggested that the treatment of the inflammatory processes involved in the pathogenesis of both psoriasis and atherosclerosis may be beneficial in reducing the CV risk in psoriatic patients. Further in-depth investigations, including prospective studies, are needed to enable more effective management of psoriatic patients in the future.

show abstract

Section: Cardiovascular Risk Assessed In Selected Examinations and Ramentioning

confidence: 99%

Cardiovascular aspects of psoriasis: an updated review

et al. 2013

View full text Add to dashboard Cite

show abstract

“…We found that 11.1% of these patients had heart failure. Several previous studies have shown that patients with EP can develop high-output heart failure ( 13 , 14 ), and that diffuse cutaneous inflammation can cause vasodilation and an increase in vascular permeability, leading to a reduction in blood pressure and peripheral edema ( 13 ). If patients have structural or functional heart defects that prohibit an increase in cardiac output, the persistent hypotension will lead to severe compensatory fluid retention, which might be the underlying cause of the pulmonary edema and congestive heart failure ( 31 ).…”

Section: Discussionmentioning

confidence: 99%

“…Another population study performed in Denmark showed that psoriasis is associated with a higher risk of MACE, similar to that associated with the conventional cardiovascular disease risk factor diabetes mellitus ( 12 ). In addition, patients with EP have been reported to be at risk of high-output heart failure ( 13 , 14 ). However, owing to the low incidence of EP, few large studies have focused on its association with cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

Heart failure in erythrodermic psoriasis: a retrospective study of 225 patients

Wu,

Yu,

Yang

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

PurposeErythrodermic psoriasis (EP) is a severe form of psoriasis that affects multiple organs, including the cardiovascular system. However, few studies have focused on this condition.This study is aimed to assess the prevalence and factors associated with heart failure in EP patient, and to the measure the serum concentrations of fibroblast growth factor 23 (FGF23), a potential predictor of chronic heart failure.MethodsWe retrospectively studied patients with EP hospitalized at Peking Union Medical College Hospital between January 2005 to October 2021. The prevalence of heart failure and associated factors was measured. In addition, peripheral blood samples were collected from 17 patients and matched with samples from eight healthy controls, and their serum concentrations of FGF23 were measured by ELISA.ResultsWe studied 225 patients with EP, with a male: female ratio of 2.7:1 and a mean age of 47.6 ± 16.7 years. Twenty-five (11.1%) participants were diagnosed with heart failure during their hospital stay. The patients with EP and heart failure were older (58.2 years vs. 46.2 years, p = 0.001); had a higher prevalence of a history of coronary heart disease (32.0% vs. 21.5%, p < 0.001), fever (48.0% vs. 23.0%, p = 0.007), infection (56.0% vs. 35.5%, p = 0.046); higher hsCRP concentration (43.2 mg/L vs. 8.2 mg/L, p = 0.005); and higher prevalence of anemia (60.0% vs. 22.0%, p < 0.001), hypoalbuminemia (64.0% vs. 42.0%, p = 0.037), and hyperlipidemia (40.0% vs. 20.0%, p = 0.023) than those without heart failure. The serum FGF23 concentration was significantly higher in patients with EP than controls (493.1 pg/ml vs. 277.8 pg/ml, p = 0.027), and was significantly lower after treatment (395.7 pg/ml vs. 463.1 pg/ml, p = 0.022).ConclusionsClinicians should be aware of the risk of heart failure in patients with EP, and especially those of advanced age and with a history of coronary heart disease, severe systemic symptoms, high concentrations of inflammatory biomarkers, and poor nutritional status.

show abstract

“…EP is often challenging to treat and a mortality rate of up to 9% has been reported [2] . EP causes systemic vasodilatation, which may lead to severe hypothermia, high-output cardiac failure, and loss of proteins and fluids [8] , [9] . Additionally, patients with EP are susceptible to infections [9] .…”

Section: Discussionmentioning

confidence: 99%

“…EP causes systemic vasodilatation, which may lead to severe hypothermia, high-output cardiac failure, and loss of proteins and fluids [8] , [9] . Additionally, patients with EP are susceptible to infections [9] . Evidence has suggested that severe psoriasis is a systemic inflammatory disease and an independent risk factor for atherosclerosis, myocardial infarction, and stroke [2] , [4] .…”

Section: Discussionmentioning

confidence: 99%

Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: A case report

Kurokawa

Hagiwara

Niijima

et al. 2018

Radiology Case Reports

View full text Add to dashboard Cite

Erythrodermic psoriasis (EP), 1 of the most rare and severe forms of psoriasis, is characterized by general erythema with silvery scales. Systemic vasodilatation in EP is potentially life-threatening, however, the degree and extent of inflammation in subcutaneous tissues are difficult to estimate accurately using standard skin inspections or ultrasound examinations. Computed tomography can be a useful modality in solving this problem. The authors report a case of EP. Sequential contrast-enhanced whole-body computed tomography before and after treatment with a tumor necrosis factor-α inhibitor (infliximab) visualized the inflammation and the effect of the treatment.

show abstract

Psoriasis-Induced Postoperative Cardiac Failure

Cited by 8 publications

References 5 publications

Cardiovascular aspects of psoriasis: an updated review

Cardiovascular aspects of psoriasis: an updated review

Heart failure in erythrodermic psoriasis: a retrospective study of 225 patients

Computed tomography imaging findings in erythrodermic psoriasis treated with infliximab: A case report

Contact Info

Product

Resources

About